OBJECTIVE: Pseudomonas aeruginosa-induced lung injury is characterized not only by the alteration in lung fluid movement but also by apoptosis of lung epithelial and endothelial cells. We studied whether inhibition of apoptosis using a broad spectrum caspase inhibitor, benzyloxycarbonyl-Val-Ala-Asp fluoromethylketone (Z-VAD.fmk), would affect lung fluid balance in rat P. aeruginosa pneumonia. METHODS: Z-VAD.fmk (3 mg/kg) was administered intravenously simultaneously with P. aeruginosa intratracheal instillation (0.5 ml/kg, 2 x 10(9) CFU/ml). Apoptosis was evaluated with the TUNEL technique, cytoplasmic oligonucleosome assay, and caspase 3 activation. To evaluate lung permeability, extravascular plasma equivalent (EPE) and lung wet to dry weight ratio (W/D) were measured 4 h after intratracheal instillation of P. aeruginosa. RESULTS: We found an increase of lung apoptosis 4 h after P. aeruginosa instillation: cytoplasmic oligonucleosome assay increased from 3.17+/-0.78 to 26.82+/-4.67 ODx1000/mg of proteins/ml, Z-VAD.fmk administration decreased this parameter to 10.3+/-2.98 ODx1000/mg of proteins/ml. Caspase 3 levels followed the same pattern. Apoptosis involved both epithelial cells and endothelial cells. Endothelial permeability was increased after Pseudomonas instillation: W/D increased from 3.75+/-0.28 in the Co group to 4.42+/-0.23 in the Pn group; EPE was also higher in the Pn group compared with the Co group (0.125+/-0.04 and 0.002+/-0.01 ml, respectively). Both of these parameters were improved after Z-VAD.fmk administration; W/D decreased to 3.36+/-0.25 and EPE to 0.02+/-0.02 ml. CONCLUSION: Apoptosis occurs in the early phase of P. aeruginosa pneumonia. Administration of Z-VAD.fmk significantly decreases DNA fragmentation and caspase 3 levels. This is associated with an improvement of endothelial permeability and lung fluid balance.
OBJECTIVE:Pseudomonas aeruginosa-induced lung injury is characterized not only by the alteration in lung fluid movement but also by apoptosis of lung epithelial and endothelial cells. We studied whether inhibition of apoptosis using a broad spectrum caspase inhibitor, benzyloxycarbonyl-Val-Ala-Asp fluoromethylketone (Z-VAD.fmk), would affect lung fluid balance in rat P. aeruginosa pneumonia. METHODS:Z-VAD.fmk (3 mg/kg) was administered intravenously simultaneously with P. aeruginosa intratracheal instillation (0.5 ml/kg, 2 x 10(9) CFU/ml). Apoptosis was evaluated with the TUNEL technique, cytoplasmic oligonucleosome assay, and caspase 3 activation. To evaluate lung permeability, extravascular plasma equivalent (EPE) and lung wet to dry weight ratio (W/D) were measured 4 h after intratracheal instillation of P. aeruginosa. RESULTS: We found an increase of lung apoptosis 4 h after P. aeruginosa instillation: cytoplasmic oligonucleosome assay increased from 3.17+/-0.78 to 26.82+/-4.67 ODx1000/mg of proteins/ml, Z-VAD.fmk administration decreased this parameter to 10.3+/-2.98 ODx1000/mg of proteins/ml. Caspase 3 levels followed the same pattern. Apoptosis involved both epithelial cells and endothelial cells. Endothelial permeability was increased after Pseudomonas instillation: W/D increased from 3.75+/-0.28 in the Co group to 4.42+/-0.23 in the Pn group; EPE was also higher in the Pn group compared with the Co group (0.125+/-0.04 and 0.002+/-0.01 ml, respectively). Both of these parameters were improved after Z-VAD.fmk administration; W/D decreased to 3.36+/-0.25 and EPE to 0.02+/-0.02 ml. CONCLUSION: Apoptosis occurs in the early phase of P. aeruginosa pneumonia. Administration of Z-VAD.fmk significantly decreases DNA fragmentation and caspase 3 levels. This is associated with an improvement of endothelial permeability and lung fluid balance.
Authors: S Hashimoto; A Kobayashi; K Kooguchi; Y Kitamura; H Onodera; H Nakajima Journal: Am J Respir Crit Care Med Date: 2000-01 Impact factor: 21.405
Authors: N B Viget; B P Guery; F Ader; R Nevière; S Alfandari; C Creuzy; M Roussel-Delvallez; C Foucher; C M Mason; G Beaucaire; J F Pittet Journal: Am J Physiol Lung Cell Mol Physiol Date: 2000-12 Impact factor: 5.464
Authors: L L Mantell; J A Kazzaz; J Xu; T A Palaia; B Piedboeuf; S Hall; G C Rhodes; G Niu; A F Fein; S Horowitz Journal: Cell Death Differ Date: 1997-10 Impact factor: 15.828
Authors: A Haimovitz-Friedman; C Cordon-Cardo; S Bayoumy; M Garzotto; M McLoughlin; R Gallily; C K Edwards; E H Schuchman; Z Fuks; R Kolesnick Journal: J Exp Med Date: 1997-12-01 Impact factor: 14.307
Authors: Peter Andrews; Elie Azoulay; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Herwig Gerlach; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Jerome Pugin; Michael Pinsky; Peter Radermacher; Christian Richard; Robert Tasker; Benoit Vallet Journal: Intensive Care Med Date: 2005-02-18 Impact factor: 17.440
Authors: Mahendra Damarla; Ahmad R Parniani; Laura Johnston; Hasina Maredia; Leonid Serebreni; Omar Hamdan; Venkataramana K Sidhaye; Larissa A Shimoda; Allen C Myers; Michael T Crow; Eric P Schmidt; Carolyn E Machamer; Matthias Gaestel; Madhavi J Rane; Todd M Kolb; Bo S Kim; Rachel L Damico; Paul M Hassoun Journal: Am J Respir Cell Mol Biol Date: 2014-05 Impact factor: 6.914
Authors: Maria Angeles Ballesteros; Marcos López-Hoyos; Pedro Muñoz; Maria Jose Marin; Eduardo Miñambres Journal: Intensive Care Med Date: 2006-09-09 Impact factor: 17.440
Authors: Eduardo Miñambres; Herminio Lopez-Escribano; María A Ballesteros; Marta Peña; Marcos López-Hoyos Journal: Intensive Care Med Date: 2005-04-21 Impact factor: 17.440
Authors: F Ader; R Le Berre; K Faure; P Gosset; O Epaulard; B Toussaint; B Polack; E Nowak; N B Viget; E Kipnis; B P Guery Journal: Infect Immun Date: 2005-07 Impact factor: 3.441
Authors: Elske van den Berg; Suzanne M Bal; Maria T Kuipers; Gustavo Matute-Bello; René Lutter; Albert P Bos; Job B M van Woensel; Reinout A Bem Journal: Physiol Rep Date: 2015-03
Authors: Laurent Robriquet; François Collet; Antoine Tournoys; Thierry Prangère; Rémi Nevière; François Fourrier; Benoît P Guery Journal: Respir Res Date: 2006-03-22